Twist Bioscience (FRA:0ME) Total Liabilities : €131.3 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Twist Bioscience Total Liabilities?

Twist Bioscience's Total Liabilities for the quarter that ended in Mar. 2024 was €131.3 Mil.

Twist Bioscience's quarterly Total Liabilities declined from Sep. 2023 (€143.33 Mil) to Dec. 2023 (€130.92 Mil) but then increased from Dec. 2023 (€130.92 Mil) to Mar. 2024 (€131.30 Mil).

Twist Bioscience's annual Total Liabilities increased from Sep. 2021 (€103.09 Mil) to Sep. 2022 (€173.71 Mil) but then declined from Sep. 2022 (€173.71 Mil) to Sep. 2023 (€143.33 Mil).

Twist Bioscience Total Liabilities Historical Data

The historical data trend for Twist Bioscience's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Twist Bioscience Total Liabilities Chart

Twist Bioscience Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Liabilities

Get a 7-Day Free Trial

31.70

53.16

103.09

173.71

143.33

Twist Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															140.09	141.02	143.33	130.92	131.30

Twist Bioscience Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Twist Bioscience's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	68.704	+	(74.185	+	0.44500000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	143.3

Total Liabilities	=	Total Assets (A: Sep. 2023 )	-	Total Equity (A: Sep. 2023 )
	=	727.49	-	584.156
	=	143.3

Twist Bioscience's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	62.091	+	(68.82	+	0.387
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	131.3

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	646.618	-	515.321
	=	131.3

Twist Bioscience Total Liabilities Related Terms

Thank you for viewing the detailed overview of Twist Bioscience's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Twist Bioscience (FRA:0ME) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Twist Bioscience Corp (FRA:0ME) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

TWST:USA 0ME:Germany

Address

681 Gateway Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.twistbioscience.com

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

Twist Bioscience (FRA:0ME) Headlines

No Headlines